Ns, considering where we are at, I think we have to hope the SC takes the case and explicitly defines the boundaries of the skinny label that is favorable to AMRN's situation. I realize that the FC has ruled for GSK, but that hasn't helped at all. Maybe AMRN can get a amicus brief filed outlining the predicament they are in.